Form 4: Sarepta Therapeutics EVP Cristin Rothfuss Reports Stock Disposals to Cover Tax Obligations

Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, reports disposals of common stock to cover tax withholding obligations related to vesting of PSUs and restricted stock units.

Summary

• Cristin Rothfuss, an EVP and General Counsel at Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 7, 2025, Rothfuss disposed of 1,131 shares of common stock at $103.7 per share to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023.
• Additionally, 347 shares were disposed of at the same price to cover tax obligations related to vesting of restricted stock units granted on March 6, 2023.
• Following these transactions, Rothfuss directly owns 11,847 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, as it simply reports required information.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance.

Stakeholder Impact

• The stock disposal has a minor dilutive effect on existing shareholders.

Key Dates